论文部分内容阅读
当前美国批准了含有白喉、破伤风类毒素和无细胞百日咳疫苗 (DTaP)在内的 4种供婴儿和小儿使用的疫苗。 2 0 0 0年 10月批准了ACEL -LMUNE(lederle实验室的制品 )和Tripedia(白喉破伤风类毒素 -无细胞百日咳菌苗 )(Aventispesteur公司 )两种制剂用于 5剂系列的DTaP疫苗 ,批准另外两种疫苗Infanrix(suithklinBeechamBiologicals)和Certiva(NorthAmericanVaccineInc)为该组疫苗的前 4剂 ,2 ,4和 6个月开始初级接种 ,并且在开始接种白喉破伤风和全细胞百日咳疫苗的这些孩子中完成DTaP组接种。本报告补充了CDC免疫实践咨询委员会的有关使用无细胞百日咳疫苗的声明 ,并概述了有关当实施第 4剂第 5剂顺序剂量时 ,无细胞百日咳疫苗反应性的咨料。这种疫苗在接种后 ,注射部位局部反应的频率和大小随剂数的增加而增加 ,这种现象存在于当前所有批准的DTaP疫苗中。在接受了第 4剂和第 5剂DTaP疫苗后 ,注射肢体的有时产生整条大腿或上臂的广泛肿胀 ,这种情况已从各公司制造商的多种制品中得到了证实。因为有关在混合系列不同厂家的DTaP药安全、免疫原性及疫苗效果的资料不足 ,ACIP推荐 ,但可能的话要尽可能使用同一品牌的DTaP疫苗。当疫苗提供者不知道或未得到以前给予类型的DTaP疫苗时 ,任何一种所批准的DTaP疫苗都
Currently, the United States has approved four vaccines for infants and children that contain diphtheria, tetanus toxoid and DTaP. In October 2000, two formulations of ACEL -LMUNE (Lederle Laboratories) and Tripedia (Tetanus Tetanus Tetanus Tetanus Tolerance) (Aventispesteur) were approved for the 5-dose series of DTaP vaccines, The other two vaccines, Infanrix (suithklin Beecham Biologicals) and Certiva (North American Vaccine Inc.), were approved for primary vaccination for the first 4, 2, 4 and 6 months of the group of vaccines, and in those children who started vaccination against diphtheria tetanus and whole-cell pertussis vaccine Complete DTaP group vaccination. This report complements the statement of the CDC Immunization Practices Advisory Committee on the use of acellular pertussis vaccine and provides an overview of advice on the reactivity of acellular pertussis vaccine when a fourth dose of a fourth dose is administered. After vaccination, the frequency and size of local reactions at the injection site increased with increasing doses of this vaccine, a phenomenon that is present in all current approved DTaP vaccines. After receiving doses 4 and 5 of the DTaP vaccine, injection of the limb sometimes produces extensive swelling of the entire thigh or upper arm, as evidenced by the wide range of articles from various manufacturers. ACIP recommends because of lack of information on the safety, immunogenicity and vaccine efficacy of DTaP drugs from different manufacturers in the mixed line, but whenever possible use the same brand of DTaP vaccine. When a vaccine provider does not know or receive a DTaP vaccine of the type previously given, any one of the approved DTaP vaccines